Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches
Executive Summary
Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.
You may also be interested in...
Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.
Novartis Finds All-Important Head Of Oncology Business At Pfizer
Novartis has tempted Liz Barrett away from Pfizer to become CEO of Novartis Oncology, but the appointment of a new global drug development head at the Swiss multinational has yet to be announced.
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Troubled Teva has been preparing employees for layoffs, but the final plan will reshape the generic drug giant entirely with 14,000 jobs being cut in a scramble to stabilize the company. Every business area and geography will be affected.